Description
China’s engagement in GHPs has witnessed a noteworthy transformation, shifting from a recipient country to an active contributor. This paper claims that the transformation of China’s role within GHPs constitutes a policy outcome arising from shifts in Beijing’s attention during the COVID-19 pandemic. It delves into the external factors that drove this shift and the resulting output, aiming to trace the causal chain within the decision-making system. While exploring the challenges of China’s participation in GHPs during the pandemic, this paper argues that alternative avenues competed with GHPs in achieving Beijing’s objectives, thereby limiting China’s engagement. Furthermore, compared to their Western counterparts, Chinese corporations face many external challenges driven by low levels of trust in GHPs, Sino-American strategic rivalry, and intrinsic hurdles related to limited engagement enthusiasm and capacity. Additionally, the challenges affecting GHPs in their procurement efforts in China are exacerbated by concerns regarding the effectiveness of Chinese vaccines and other medical products.
